More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/ODQ [41443-28-1]
Chemical Structure
Chemical Structure
Chemical Structure

ODQ [41443-28-1]

Research Use Only
AG-CR1-3500
AdipoGen Life Sciences
CAS Number41443-28-1
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight187.2
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    ODQ [41443-28-1]
  • Delivery Days Customer
    10
  • CAS Number
    41443-28-1
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Warning
  • Molecular Formula
    C9H5N3O2
  • Molecular Weight
    187.2
  • Scientific Description
    Chemical. CAS: 41443-28-1. Formula: C9H5N3O2. MW: 187.2. Potent and highly selective, irreversible inhibitor of soluble guanylyl cyclase (sGC). The binding is competitive with nitric oxide (NO). Tool to elucidate the nitric oxide (NO)-cGMP pathway. Apoptosis inhibitor Inhibits growth and migration of prostate cancer cells independent of its effects on GMP levels. - Potent and highly selective, irreversible inhibitor of soluble guanylyl cyclase (sGC). The binding is competitive with nitric oxide (NO) [1-5]. Tool to elucidate the nitric oxide (NO)-cGMP pathway [1-5]. Apoptosis inhibitor [6] Inhibits growth and migration of prostate cancer cells independent of its effects on GMP levels [6].
  • SMILES
    O=C1ON=C2C=NC3=CC=CC=C3N12
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

References

  • Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase: C.L. Boulton, et al.; Neuroscience 69, 699 (1995)
  • Novel guanylyl cyclase inhibitor, ODQ reveals role of nitric oxide, but not of cyclic GMP in endothelin-1 secretion: F. Brunner, et al.; FEBS Lett. 376, 262 (1995)
  • Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one: J. Garthwaite, et al.; Mol. Pharmacol. 48, 184 (1995)
  • Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase: A. Schrammel, et al.; Mol. Pharmacol. 50, 1 (1996)
  • Inhibition of Soluble Guanylate Cyclase by ODQ: Y. Zhao, et al.; Biochemistry 39, 10848 (2000)
  • cGMP-independent anti-tumour actions of the inhibitor of soluble guanylyl cyclase, ODQ, in prostate cancer cell lines: G. Haramis, et al.; Br. J. Pharmacol. 155, 804 (2008)